Christopher Liu
Stock Analyst at Leerink Partners
(2.43)
# 2,266
Out of 4,826 analysts
5
Total ratings
50%
Success rate
18.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.28 | +449.62% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $20.93 | +29.00% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $77.56 | -45.84% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $39.60 | -54.55% | 1 | Aug 8, 2023 | |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.28
Upside: +449.62%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $20.93
Upside: +29.00%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $77.56
Upside: -45.84%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $39.60
Upside: -54.55%